In vitro evaluation shows improved drug release in patches formulated with doxazosin mesylate, indicating enhanced delivery efficacy.
Key Points
Maximum drug release achieved in 12 hours, indicating effective transdermal delivery of doxazosin mesylate.
Formulation utilized the solvent casting method with varying ratios of HPMCK100 and PVP K30 polymers for optimal results.
Evaluation included drug release studies and kinetics, revealing first-order drug release and diffusion processes.
Study highlights improvement in bioavailability over traditional oral delivery methods, suggesting a potential advance in treatment for benign prostatic hyperplasia.